Companies to Watch – Elegen
In the last of four features on Elegen, we present a case study of how Elegen’s cell-free ENFINIA™ DNA accelerates projects with high sequence complexity from the drawing board to the incubator, saving weeks to advance research goals faster.
This is part 4 of the Big4Bio Company to Watch program for April 2024: Elegen
For more information on the series, click here.